Kyverna Therapeutics (KYTX) announced the appointment of Mayo Pujols as its Chief Technology Officer, CTO, effective February 9, 2026. Most recently, Pujols served as Chief Operating Officer of Castle Creek Biosciences
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics: Strong Early Autoimmune CAR-T Data, Accelerated SPS Timeline, and Solid Cash Runway Support Buy Rating
- Kyverna Therapeutics Names Christi Shaw Executive Board Chair
- Kyverna Therapeutics provides corporate update, priorities for 2026
- Kyverna Therapeutics Announces $100 Million Public Offering
- Midday Fly By: Warner Bros. urges investors to reject Paramount bid